Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571526 | 0.91 | P2RX7 (0.70) | P2RX7 | |
| SCHEMBL7455062 | 0.86 | SMN1; SMN2 (0.55) | P2RX7 | |
| SCHEMBL7571588 | 0.83 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL6574267 | 0.82 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL2709399 | 0.81 | MAPT (0.61) | P2RX7 | |
| SCHEMBL4130035 | 0.81 | P2RX7 (0.77) | P2RX7 | |
| SCHEMBL4129828 | 0.81 | P2RX7 (0.77) | P2RX7 | |
| SCHEMBL6573881 | 0.81 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL7571579 | 0.81 | P2RX7 (0.77) | P2RX7 | |
| SCHEMBL4877418 | 0.80 | P2RX7 (0.83) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | claimed |
| US-6303659-B2 | Compounds | ASTRAZENECA AB (SE) | 2001-10-16 | — | — | US | claimed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | claimed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | claimed |
| EP-1716851-B1 | THIOAMIDES AND SALTS THEREOF AND CYTOKINE PRODUCTION INHIBITORS CONTAINING BOTH | ISHIHARA SANGYO KAISHA (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-7632865-B2 | Thioamides and salts thereof and cytokine production inhibitors containing both | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-12-15 | — | — | US | disclosed |
| CN-100467447-C | Thioamide compound or its salt and cytokine production inhibitor containing the same | ISHIHARA SANGYO KAISHA (JP) | 2009-03-11 | — | — | CN | disclosed |
| US-20070219215-A1 | Thioamides and Salts Thereof and Cytokine Production Inhibitors Containing Both | ISHIHARA SANGYO KAISHA, LTD (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-1918118-A | Thioamide compound or its salt and cytokine production inhibitor containing the same | ISHIHARA SANGYO KAISHA (JP) | 2007-02-21 | — | — | CN | disclosed |
| EP-1716851-A1 | THIOAMIDES AND SALTS THEREOF AND CYTOKINE PRODUCTION INHIBITORS CONTAINING BOTH | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-6720452-B2 | SUBSTITUTED BENZMIDE-N-METHYL ADMANATANE DERIVATIVES USEFUL FOR TREATMENT OF RHEUMATOID ARTHRITIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ASTRAZENECA AB (SE) | 2004-04-13 | — | — | US | disclosed |
| EP-1240132-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20020193414-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | US | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6303659-B2 | Compounds | ASTRAZENECA AB (SE) | 2001-10-16 | — | — | US | disclosed |
| US-6258838-B1 | Compounds | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | disclosed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | disclosed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219215-A1 | Thioamides and Salts Thereof and Cytokine Production Inhibitors Containing Both | IFNG, TST, STAT6 | P2RX7 2749/4885 |
| US-20020193414-A1 | Adamantane derivatives | APP, ADORA1, ADAM17 | P2RX7 894/4885 |
| US-20010003121-A1 | Novel compounds | APP, BACE1, CHRNA5 | P2RX7 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.